What is B. Riley’s Estimate for Geron FY2027 Earnings?

Geron Co. (NASDAQ:GERN) – Equities research analysts at B. Riley decreased their FY2027 earnings per share estimates for Geron in a research report issued to clients and investors on Tuesday, February 18th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will post earnings of $0.28 per share for the year, down from their prior estimate of $0.36. B. Riley currently has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

A number of other equities analysts also recently commented on GERN. Needham & Company LLC boosted their price objective on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Finally, Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron has an average rating of “Moderate Buy” and a consensus price target of $6.91.

Geron Stock Down 3.4 %

Shares of NASDAQ GERN opened at $2.54 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.94 and a beta of 0.53. The stock has a 50 day moving average price of $3.16 and a 200 day moving average price of $3.89. Geron has a 52-week low of $1.64 and a 52-week high of $5.34.

Hedge Funds Weigh In On Geron

A number of large investors have recently made changes to their positions in GERN. SG Americas Securities LLC increased its position in shares of Geron by 32.6% during the third quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 5,559 shares in the last quarter. Creative Planning increased its position in shares of Geron by 23.8% in the 3rd quarter. Creative Planning now owns 92,784 shares of the biopharmaceutical company’s stock valued at $421,000 after acquiring an additional 17,837 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in shares of Geron by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 341,884 shares of the biopharmaceutical company’s stock valued at $1,552,000 after acquiring an additional 88,027 shares during the period. Values First Advisors Inc. increased its position in shares of Geron by 13.6% in the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 3,668 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Geron by 23.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,094 shares during the period. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.